Health Condition 1: D59- Acquired hemolytic anemia Health Condition 2: L10-L14- Bullous disorders Health Condition 3: L20-L30- Dermatitis and eczema Health Condition 4: L60-L75- Disorders of skin appendages Health Condition 5: N00-N08- Glomerular diseases Health Condition 6: M05-M14- Inflammatory polyarthropathies Health Condition 7: L80-L99- Other disorders of the skin and subcutaneous tissue Health Condition 8: M35- Other systemic involvement of connective tissue Health Condition 9: L40-L45- P
Conditions
Interventions
Intervention1: Metformin: Metformin 500 mg tablet once daily for one week followed by twice daily for the second week and thrice daily from the third week onward till twelve weeks
Control Intervention
Sponsors
JIPMER
Eligibility
Inclusion criteria
Inclusion criteria: 1)Non-diabetic, steroid-naive patients or receiving a dose of less than or equal to 5 mg prednisolone equivalent per day and being started on oral glucocorticoids of more than or equal to 20 mg prednisolone or an equivalent dose of another glucocorticoid per day 2)Planned maintenance dose of glucocorticoids after tapering will be more than or equal to 7.5 mg prednisolone or an equivalent dose of other glucocorticoid per day for at least 12 weeks
Exclusion criteria
Exclusion criteria: 1)Preexisting diabetes mellitus 2)Patients receiving intravenous glucocorticoids 3)Renal insufficiency(estimated glomerular filtration rate less than 60ml/min/1.73m2) 4) Deranged liver function tests (Alanine transaminase and aspartate transaminase more than 2.5 times upper limit of normal) 5) Any chronic illness like chronic infection, chronic heart failure, malignancy, etc. 6) Pregnancy and lactation 7) Current alcohol intake of more than 20g per day for males and more than 10g per day for females or substance use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients dysglycemiaTimepoint: baseline and three months | — |
Secondary
| Measure | Time frame |
|---|---|
| Area under curve blood glucoseTimepoint: baseline and three months;Body compositionTimepoint: baseline and three months;Homeostatic model assessment(HOMA) indicesTimepoint: baseline and three months;Lipid profileTimepoint: baseline and three months | — |
Countries
India
Contacts
Public ContactDr Jayaprakash Sahoo
JIPMER
Outcome results
None listed